Table 2.

Main characteristics of studies evaluating cancer risk associated with miR-149 rs2292832 C/T which included in the current meta-analysis.

N	References	Country	Ethnicity	Genotyping method	Design	Cases/Controls	Genotype distributiona		Cancer type	Quality score	PHWE
							Cases	Controls
1	He J. et al., 2018	China	Asian	TaqMan	HB	380/791	32/62/286	59/172/560	NB	10	2.98e−14
2	Ranjbar et al., 2018	Iran	Asian	PCR-RFLP	PB	73/70	8/14/51	4/24/42	CRC	8	0.92
3	Cîmpeanu et al., 2017	Romania	Caucasian	TaqMan	HB	142/288	70/49/23	126/120/42	GC	10	0.15
4	Tandon et al., 2017	India	Asian	PCR-RFLP	HB	200/200	140/37/23	174/16/10	OC	9	7.96e−12
5	Gu and Tu, 2016	China	Asian	PCR-RFLP	HB	186/186	55/89/42	60/87/39	GC	7	0.54
6	Hashemi et al., 2016	Iran	Asian	t-ARMS-PCR	HB	169/182	77/68/24	101/57/24	PC	6	0.002
7	Jiang et al., 2016	China	Asian	MassARRAY	PB	869/955	65/164/640	66/204/685	GC	12	8.88e−16
8	Li H. et al., 2016	China	Asian	TaqMan	PB	555/395	49/252/254	42/176/177	LC	13	0.92
9	Miao et al., 2016	China	Asian	Array	HB	575/1,548	61/231/283	175/647/726	HNSCC	12	0.10
10	Ni and Huang, 2016	China	Asian	PCR-RFLP	HB	155/342	47/82/26	108/179/55	OvC	9	0.20
11	Su et al., 2016	China	Asian	PCR-RFLP	HB	245/315	108/112/25	149/140/26	GC	10	0.44
12	Yang et al., 2016	China	Asian	PCR-RFLP	PB	30/98	3/16/11	9/49/40	KS	9	0.35
13	Dong et al., 2015	China	Asian	MassARRAY	PB	369/751	63/175/131	91/339/321	PTC	12	0.96
14	He et al., 2015	China	Asian	Mass-ARRAY	PB	450/450	36/183/231	60/188/202	BC	11	0.14
15	Liu, 2015	China	Asian	PCR-RFLP	PB	266/266	91/130/45	108/124/34	HCC	12	0.76/
16	Pratedrat et al., 2015	Thailand	Asian	TaqMan	HB	104/95	11/27/66	9/24/62	HCC	8	0.018
17	Sushma et al., 2015	India	Asian	PCR-RFLP	PB	100/102	72/22/6	90/12/0	OC	9	0.79
18	Yan et al., 2015	China	Asian	PCR-RFLP	HB	274/328	66/133/75	72/156/100	HCC	10	0.50
19	Chu et al., 2014	Taiwan	Asian	PCR-RFLP	PB	188/337	13/36/139	27/64/246	HCC	11	8.9e-10
20	Dikeakos et al., 2014	Greece	Caucasian	PCR-RFLP	HB	163/480	21/73/69	33/198/249	GC	9	0.50
21	Du et al., 2014	China	Asian	TaqMan	PB	355/362	47/163/145	37/148/177	RCC	12	0.52
22	Kou et al., 2014	China	Asian	PCR-RFLP	PB	270/532	113/122/35	202/253/77	HCC	10	0.93
23	Liu et al., 2014	China	Asian	PCR-RFLP	PB	327/327	84/143/100	56/138/133	HCC	11	0.066
24	Pu et al., 2014	China	Asian	PCR-RFLP	HB	187/459	22/31/134	48/103/308	GC	9	8.5e-13
25	Wang R. et al., 2014	China	Asian	MassARRAY	HB	772/717	83/318/371	56/309/352	HCC	9	0.33
26	Wang X. H. et al., 2014	China	Asian	PCR-RFLP	PB	152/304	13/72/67	43/148/113	HCC	11	0.68
27	Wei et al., 2014	China	Asian	MassARRAY	PB	838/1,006	105/354/379	86/424/496	PTC	14	0.77
28	Ahn et al., 2013	South Korea	Asian	PCR-RFLP	PB	461/447	44/176/241	40/187/220	GC	12	0.94
29	Hu et al., 2013	China	Asian	Sequencing	HB	680/690	70/297/313	78/302/310	Glioma	14	0.78
30	Huang et al., 2013	China	Asian	PCR-RFLP	PB	158/242	22/67/69	39/113/90	NPC	11	0.8
31	Lv et al., 2013	China	Asian	PCR-RFLP	PB	347/459	30/64/253	48/103/308	CRC	10	8.5e-13
32	Min et al., 2012	South Korea	Asian	PCR-RFLP	PB	446/502	48/177/221	51/219/232	CRC	12	0.97
33	Vinci et al., 2013	Italy	Caucasian	HRMA	HB	160/178	79/58/23	86/75/17	CRC	9	0.95
34	Chu et al., 2012	Taiwan	Asian	PCR-RFLP	PB	470/425	37/88/345	26/84/315	OC	10	1.1e-7
35	Kim et al., 2012	South Korea	Asian	PCR-RFLP	PB	159/201	14/64/81	21/97/83	HCC	11	0.40
36	Tu et al., 2012	Taiwan	Asian	PCR-RFLP	PB	273/122	20/129/124	21/52/49	HNSCC	7	0.33
37	Zhang M. et al., 2012	China	Asian	PCR-RFLP	PB	245/229	23/102/120	24/113/92	BC	13	0.25
38	Zhang M. W. et al., 2012	China	Asian	PCR-RFLP	PB	443/435	50/190/203	46/202/187	CRC	14	0.48
					PB	274/269	41/101/132	35/120/114	GC	14	0.77
39	Vinci et al., 2011	Italy	Caucasian	HRMA	HB	101/129	44/41/16	65/53/11	LC	9	0.89
40	Kontorovich et al., 2010	Israel	Asian	MassARRAY	PB	167/122	87/40/40	53/30/39	Cancer	9	6.5e-8
41	Liu et al., 2010	USA	Caucasian	PCR-RFLP	HB	1,109/1,130	580/441/88	586/445/99	HNSCC	13	0.29
42	Hu et al., 2009	China	Asian	PCR-RFLP	PB	1,009/1,093	450/460/99	482/503/108	BC	14	0.17
43	Tian et al., 2009	China	Asian	PCR-RFLP	PB	1,058/1,035	123/472/463	112/453/470	LC	14	0.89

Genotype distributions are sorted as CC/CT/TT.

^aGenotype distributions are sorted as CC/CT/TT. PB, population-based design; HB, hospital-based design; BC, Breast cancer; CRC, Colorectal cancer; GC, Gastric cancer; HCC, Hepatocellular carcinoma; HNSCC, Head and neck squamous cell carcinoma; LC, Lung cancer; NB, Neuroblastoma; NC, Nasopharyngeal carcinoma; NSCLC, non-Small cell lung carcinoma; OC, Oral cancer; OvC, Ovarian cancer; PC, Prostate cancer; PTC, Papillary thyroid carcinoma; RCC, Renal cell carcinoma; KS, Kaposi sarcoma.